Slowdown casts doubt on biotech offerings
Slowdown casts doubt on biotech offerings After a two-year capital drought, seven biotechnology and life sciences companies made initial public […]
Slowdown casts doubt on biotech offerings After a two-year capital drought, seven biotechnology and life sciences companies made initial public […]
Machine Could Sequence Human Genome in a Year A new gene-reading machine is so much faster than existing technology that
Biotech Raises More Cash in 2003 But Europe Weak The global biotechnology industry raised more money by the end of
Biotech Raises More Cash in 2003 But Europe Weak Read Post »
Is That Daylight for ImClone? The beleaguered drugmaker finally gets some good news with Swiss approval of its cancer-fighting drug
Over the Rainbow Yet? Consolidation slows, valuations grow, and now hope for some IPOs
Ultimate Analysis With the necessary tools at hand, the race is on to build � and market � the first
COUNTERING COUNTERFEITS Industry offers proposals to fight growing problem of fake drugs.
BAYER CHEMICALS TO TAKE A SPIN Split-off of chemicals will shift firm�s focus to life sciences
BIOTECH SCORES BIG THIRD-QUARTER GAINS Substantial revenue and earnings growth continued unabated for yet another quarter
DRUG EARNINGS RALLY IN THE THIRD QUARTER Major pharmaceutical firms see improvement in sales and earnings as the year progresses
Get new actionable insights and updates from BiotechBlog